Title: Effect of Immunotherapy on Patients with Bronchial Asthma
Authors: Ali M. Algamdi, Muslah S. Alalyany
DOI: https://dx.doi.org/10.18535/jmscr/v11i6.22
Abstract
Immunotherapy, also known as allergen-specific immunotherapy or desensitization, involves gradually increasing doses of specific allergens to induce immune tolerance and modify the allergic response. The therapy aims to alleviate symptoms, reduce medication usage, and potentially modify the underlying disease process. Several studies have investigated the effects of immunotherapy on asthma patients, providing insights into its clinical efficacy and safety.
Research studies have shown positive outcomes of immunotherapy in bronchial asthma. A randomized controlled trial demonstrated significant improvements in asthma symptoms, decreased medication use, and reduced airway hyperresponsiveness in patients who received subcutaneous immunotherapy compared to the placebo group. Another study focusing on children showed improvements in lung function and reduced asthma exacerbations with sublingual immunotherapy.
Long-term effects of immunotherapy were explored in a prospective cohort study on adults with moderate-to-severe persistent allergic asthma. The study found sustained improvements in asthma control, reduced rescue medication use, and a decreased risk of exacerbations in patients who received immunotherapy compared to those who did not.
References
- Viegi, G., Maio, S., Pistelli, F., Baldacci, S., & Carrozzi, L. (2006). Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution. Respirology, 11(5), 523-532.
- Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., & Wallace, D. (2011). Allergen immunotherapy: a practice parameter third update. Journal of Allergy and Clinical Immunology, 127(1), S1-S55.
- Blumberga, G., Groes, L., Haugaard, L., & Dahl, R. (2006). Steroid‐sparing effect of subcutaneous SQ‐standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy, 61(7), 843-848.
- Bahceciler, N. N., Arikan, C., Taylor, A., Akdis, M., Blaser, K., Barlan, I. B., &Akdis, C. A. (2005). Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. International archives of allergy and immunology, 136(3), 287-294.
- Kwah, J. H., & Peters, A. T. (2019, November). Asthma in adults: Principles of treatment. In Allergy & Asthma Proceedings (Vol. 40, No. 6).
- Moote, W., Kim, H., & Ellis, A. K. (2018). Allergen-specific immunotherapy. Allergy, Asthma & Clinical Immunology, 14(2), 1-10.
- Hedlin, G., Wille, S., Browaldh, L., Hildebrand, H., Holmgren, D., Lindfors, A., Nordvall, S. L., & Lowenstein, H. (1999). Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. The Journal of allergy and clinical immunology, 103(4), 609–614.
- Bousquet, J., & Michel, F. B. (1994). Specific immunotherapy in asthma. Allergy proceedings: the official journal of regional and state allergy societies, 15(6), 329–333.
- Martín Muñoz M. F. (2004). Eficacia de la inmunoterapia en eltratamiento del asma [Efficacy of immunotherapy in the treatment of asthma]. Allergologia et immunopathologia, 32(3), 133–141.